ClinicalTrials.gg
CompletedNCT04315987HOPEUpdated Oct 28, 2022

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

A Phase 2 interventional study of NestaCell® and Placebo in COVID-19 Pneumonia, sponsored by Azidus Brasil. Completed at 4 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-28.

Sponsored by Azidus Brasil · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in COVID-19 by Azidus Brasil — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · Azidus Brasil.

Enrollment
6th of 10
90 · median 145
Started
2020
with 6 others
Phase 2
3 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in COVID-19 by Azidus Brasil, this one is the 6th largest by enrollment, is one of 7 that started in 2020, is one of 3 in phase 2, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 10 studies in COVID-19 by Azidus Brasil is open now. Recruiting first, the newest first:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in COVID-19 by Azidus Brasil, or all of them as a file.
02

Study summary

This is phase II study to assess the efficacy of NestaCell® (mesenchymal stem cell) to treat severe COVID-19 pneumonia.

Read the detailed description

The number of infections of COVID-19 worldwide has killed thousands and is continually rising. The novel coronavirus attacks the human body by attaching to the angiotensin-converting enzyme-2 (ACE2), a protective enzyme against lung damage. In addition, the cellular serine protease TMPRSS2 for HCoV-19 Spike protein priming is also essential for the host cell entry and spread. Coronaviruses can be deadly, in large part because they cause "cytokine storms." These storms result from imbalances between pro-inflammatory and anti-inflammatory proteins called cytokines, which can cause extreme inflammation and respiratory complications. Respiratory distress kills hundreds of thousands of people each year worldwide, and hundreds of clinical trials are testing drugs to treat it.

MSCs have been widely used in cell-based therapy, from basic research to clinical trials Safety and effectiveness have been clearly documented in many clinical trials, especially in the immune-mediated inflammatory diseases.

NestaCell® is a mesenchymal stem cell therapy produced by Cellavita and proved to be safe in previous clinical trials.

The aim of this study is assess the efficacy of NestCell® as an add-on therapy to standard treatment to treat patients with severe COVID-19 pneumonia. .

Patients included will be randomized to receive 2x10\^7 cells (20 million cells) on days 1, 3, 5 and 7.

03

Conditions studied

  • COVID-19 Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥ 18 years 2. Present a confirmed or pending diagnosis of COVID-19, but with tomographic and clinical signs strongly suggestive of SARS-CoV-2 infection (COVID-19), with pulmonary impairment greater than or equal to 50% and: i. Oxygen saturation \<95%; ii. CURB-65 rating ≥ a 4; d) Participants with a score on WHO ordinal scale that measures illness severity over time equal to 5 (Hospitalized with non-invasive ventilation or high-flow oxygen).

Exclusion criteria

Exclusion Criteria:

  1. Patients with diseases in the past or screening;
  2. Those who have serious basic diseases that affect their survival, including: malignant tumor, hematopathy, malignant fluid, active hemorrhage, severe malnutrition, etc. which have not been controlled and can not be removed due to multiple ;
  3. Known or self-reported or syphilis infected persons;
  4. Have participated in stem cell clinical research;
  5. Pregnant or lactating women or those who have fertility plans in the past year;
  6. The estimated life cycle is less than 48 hours;
  7. Other conditions that the researcher thinks are not suitable for participating in the experiment.
  8. Shock
  9. Continuous use of agents or organ transplants in the past 6 months;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    NestaCell®

    A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.

    Biological: NestaCell®

  • Placebo comparator
    Placebo

    Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.

    Biological: Placebo

Interventions

  • BiologicalNestaCell®

    A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.

    Also known as: Mesenchymal Stem Cell

  • BiologicalPlacebo

    Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.

06

What researchers measure

Primary outcomes

  1. Change in Clinical Condition

    Ordinal scale (WHO ordinal scale that measures illness severity over time)

    Time frame: 10 days

Secondary outcomes

  1. Rate of mortality within 10-days

    Evaluation of Pneumonia change

    Time frame: 10 days

  2. Change of Clinical symptoms - respiratory rate

    Evaluation of Pneumonia change

    Time frame: 10 days

  3. Hypoxia

    oxygen saturation

    Time frame: 10 days

  4. PaO2 / FiO2 ratio

    oxygen saturation

    Time frame: 10 days

  5. CD4+ and CD8+ T cell count

    Marker of Immunological function

    Time frame: Days 1, 2, 4, 6 and 8.

  6. Changes of blood oxygen

    PaO2 / FiO2 ratio

    Time frame: 10 days

  7. Side effects in the treatment group

    Number of participants with treatment-related adverse events

    Time frame: 10 days

  8. Complete blood count, cardiac, hepatic and renal profiles;

    Complete blood count, ALT, AST, GGT, CK, CKmB and creatinine

    Time frame: Days 1, 2, 4, 6 and 8.

07

Study locations

4 sites
  • Hospital Vera Cruz
    Campinas, São Paulo, Brazil
  • Hospital de Barueri
    São Paulo, Brazil
  • IncCOR
    São Paulo, Brazil
  • UNIFESP
    São Paulo, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided — It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2021, 7 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 7 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2020
First posted
Mar 20, 2020
StartActual
Jun 30, 2020
Primary completionActual
Feb 28, 2021
CompletionActual
Feb 28, 2021
Last update
Oct 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04315987
Lead sponsor
Azidus Brasil
Collaborators
Cellavita Pesquisa Científica Ltda, Hospital Vera Cruz
Responsible party
Sponsor
First posted
Mar 20, 2020
Start date
Jun 30, 2020
Primary completion
Feb 28, 2021
Completion
Feb 28, 2021
Last update
Oct 28, 2022

Study contacts

Florentino de Araujo Cardoso Filho
principal investigator · Hospital Vera Cruz

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesenchymal Stem Cell

Start the discussion